COMPANY PROFILE

Recursion Pharma

A clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery

Salt Lake City, United StatesFounded 2013Biotech & Life Sciences

Valuation $1.01B Market cap · Aug/2026

Revenue $65M Latest reported FY

At a glance

Status: Listed
Founded: 2013
Headquarters: Salt Lake City, United States
Listing: IPO 2021
Sector: Biotech & Life Sciences
Power Law: Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

32 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

CNCentral Texas Angel Network
BFBill & Melinda Gates Foundation

Series A11 investors entered at this stage

DCDCVC
AVAME Cloud Ventures
SVSahsen Ventures
FEFelicis
EVEPIC Ventures
NTNat Turner
LCLux Capital
APAmplify Partners
WIWild Basin Investments
DBDavid Beyer
OVObvious Ventures

Series B and later19 investors entered at this stage

CCCasdin Capital
PMPlatinum Asset Management
IHIntermountain Healthcare
TVTwo Sigma Ventures
ACAdvantage Capital
SBSamsara BioCapital
MCMubadala Capital
UUUniversity of Utah
LBLeaps by Bayer
CMCatalio Capital Management
KIKinnevik
TITwo Sigma Investments
IVIntermountain Ventures
BGBaillie Gifford
INInvus
LMLaurion Capital Management
MVMenlo Ventures
CRCRV
STScottish Mortgage Investment Trust

Talent

Book a demo to see the people

Employees mapped 942 incl. 83 AI specialists

Founders /100 quality score

Key operators 52 quality /100

Potential founders likely future founders

Startup mafia 11 alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Alumni founders

5 of 11 startups shown

Former Recursion Pharma employees who went on to found companies, sorted by Dealroom signal score.

Retro BiosciencesEst. 2020

Joe Betts-LacroixUnited States

Signal score94

Enveda BiosciencesEst. 2019

Viswa ColluruUnited States

Signal score93

NoetikEst. 2022

Ron Alfa, MD, PhDUnited States

Signal score90

AchiraEst. 2024

Zavain DarUnited States

Signal score87

FHFlax HealthEst. 2025

David KartchnerUnited States

Signal score84

6 more alumni-founded companies in this previewBook a demo

Global footprint

Workforce and web traffic by country

Workforce by country

15 countries with
team presence

🇺🇸 United States58.7%

🇬🇧 United Kingdom30.1%

🇨🇦 Canada9.2%

🇦🇹 Austria0.4%

🇵🇱 Poland0.3%

Top 5 of 15 shown

Web traffic by country

94K monthly visits
across markets

🇺🇸 United States20.9%

🇮🇳 India9.1%

🇬🇧 United Kingdom9.1%

🇳🇿 New Zealand4.9%

🏳️ Korea4.8%

Top 5 markets shown

Patents

Estimated portfolio value

$23M

117 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Recursion Pharma was the backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

5 deals across Recursion Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount

By stageCount

By periodCount

Where Recursion Pharma deploys vs peers

Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

Compare against